

Special Issue

Innovative Applications of Targeted Nanocarriers and Photodynamic Therapy in the Treatment of Neurological Diseases and Tumors

Message from the Guest Editors

The treatment of neurological disorders such as neurodegenerative diseases and brain tumors remains challenging because the presence of the blood–brain barrier (BBB) renders treatments ineffective, as many potentially therapeutic drugs cannot enter the brain at therapeutic levels. As a result, new therapeutic strategies are urgently needed to overcome these problems and to cure diseases definitively without causing side effects. Photodynamic therapy has emerged as a promising alternative due to its anticancer efficacy and drug conjugation for targeted drug delivery using nanomaterials. Therefore, it is of interest to understand the current potential of photodynamic therapy as a nanotherapy for the treatment of neurological disorders. In addition to understanding its advantages, it is also important to understand its disadvantages in order to gain a perspective on its feasibility and challenges in the face of mainly neurodegenerative diseases and brain tumors.

Guest Editors

Dr. Emma Ortiz-Islas

Dr. Victoria Campos-Peña

Dr. Citlali Ekaterina Rodríguez Pérez

Deadline for manuscript submissions

30 September 2025



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/231634

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).